Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/20/2010

NEW YORK and JERUSALEM, Sept. 21 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Wednesday, September 22, 2010 at 11:00 AM (ET).

Chiasma is currently conducting its second clinical trial of the investigational new drug Octreolin™, an oral form of octreotide acetate that uses the proprietary Transient Permeability Enhancer (TPE) system for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  A third clinical trial is planned to start by the end of 2010. The Food and Drug Administration has granted orphan drug designation for Octreolin and the Company will submit an application for Orphan Medicinal Product Designation to the European Medicines Agency (EMA) shortly.

Upon receipt of positive Phase 3 efficacy and safety data, the Company will submit an NDA using the "505(b)(2) regulatory pathway" in the United States and its equivalent, the "Hybrid Application," in Europe.

Chiasma is also developing Octreolin as a potential treatment for patients with portal hypertension (PHT); there are currently no drugs approved for PHT in the U.S.

About Chiasma

Chiasma is evaluating the TPE technology with approved drugs, which may enable their being switched from injectable to oral, and potentially may also result in new indications or otherwise improved labels.  The TPE technology promotes the delivery of drugs to the GI wall and from there to the liver.  It is applicable to macromolecules that, to date, can be administered only by injection.  TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.  The Company has successfully demonstrated proof-of-principle in
'/>"/>

SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly
2. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
3. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
4. Caliper Life Sciences CEO to Present Keynote Presentation at MipTec European Conference
5. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
6. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
7. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
8. CryoLife to Present at UBS Global Life Sciences Conference
9. Sigma-Aldrich to Present at the UBS Global Life Sciences Healthcare Conference on Tuesday, September 21, 2010
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 One of the major ... personalized medicine, which is the practice of using genomic ... a patient,s individual biology. Personalized diagnostics—laboratory analyses that inform ... in the lab,s future. This fall, AACC ,s ... latest science in this exciting field and the novel ...
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... MARKETS , that the global market RNA interference (RNAi) ... $38.8 billion by 2018, with a five-year compound annual ... the fastest moving segment of the market, is moving ... RNAi therapeutics has shown tremendous growth and has moved ...
(Date:7/31/2014)... (PRWEB) August 01, 2014 ... China Polyurethane Resin Industry” is a professional ... market. The report introduces Polyurethane Resin basic ... industry chain structure and industry overview. This ... China’s domestic market as well as global ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2
... , SAN FRANCISCO, Aug. 11 ... stage biopharmaceutical company developing a proprietary breakthrough class of targeted ... private placement financing with gross proceeds of US $5,123,521, exceeding ... anticipated on or before September 15, 2009, with additional proceeds ...
... , , CAMBRIDGE, Mass., Aug. 11 ... of novel therapies for immune-mediated diseases, today announced changes to the protocol ... and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with ... ( D urable Response Therapy E valuation F or ...
... SEATTLE, Aug. 11 Omeros Corporation today announced ... OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is ... agent that causes pupil dilation (mydriasis), each with well-known ... Omeros, Phase 1/Phase 2 trial enrolled 61 patients undergoing ...
Cached Biology Technology:Jennerex Closes $5 Million First Tranche of Series C Financing 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2
(Date:7/31/2014)... enormous conflagration known as the Rim Fire was in ... mature trees, when it entered the backcountry of Yosemite ... 2013. But inside the park, the battle began to ... decisions and drought can combine to fuel large, severe ... it eventually encountered lands where fire had been used ...
(Date:7/31/2014)... are familiar with Hibiscus flowers- they are an ... are commonly planted in the landscape. Some, like ... endangered species. , Only a relatively few botanists ... an equally beautiful and intriguing related group of ... of Hibiscus". , Brother of Hibiscus species are ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2Hope for the overweight 2
... Washington, DC Engineered nanoscale materials (ENMs), which ... use in food packaging, raise new safety evaluation ... report released today by the Project on Emerging ... The food-packaging industry, food companies and ...
... developed an effective technology for reducing contamination of dangerous ... Salmonella and E. coli O157:H7 on foods ranging from ... It is made from inexpensive and readily available ingredients ... and Drug Administration. The new technology, which ...
... Almost every June for 30 years, Terry McEneaney drove around ... three routes. Park ornithologist at the time, he would ... Then he,d drive another half mile, repeat the process and ... for the North American Breeding Bird Survey. Trying to finish ...
Cached Biology News:Use of nanomaterials in food packaging poses regulatory challenges 2New UGA invention effectively kills foodborne pathogens in minutes 2Bird watchers, space technology come together in Montana State University study 2Bird watchers, space technology come together in Montana State University study 3
Recombinant Rhesus Macaque IFN-alpha...
chk 1 kinase...
...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: